Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 30, 2003
IMPAX Comments on Shire's Lawsuit Related to Generic Version of Adderall XR
Dec 24, 2003
IMPAX Receives FDA Tentative Approval for Generic Versions Of OxyContin; Ninth ANDA Approval in 2003
Dec 04, 2003
IMPAX to Present at First Albany Growth Conference
Nov 30, 2003
MPAX Receives FDA Approval for Generic Claritin Reditabs
Nov 19, 2003
IMPAX ANDA Filing for Generic Version of Adderall XR Accepted by FDA
Nov 18, 2003
IMPAX Added to NASDAQ Biotech Index Effective November 24, 2003
Nov 09, 2003
IMPAX Comments on Alza's Lawsuit Related to Generic Version Of Ditropan XL
Nov 05, 2003
IMPAX Receives FDA Tentative Approval for Generic Versions Of OxyContin; Ninth ANDA Approval in 2003
Nov 05, 2003
IMPAX Reports Third Quarter Financial Results; Company Continues to Post Record Quarterly Revenues; Four FDA Approvals Received in the Quarter
Nov 04, 2003
IMPAX to Present at CIBC World Markets Annual Healthcare Conference
Nov 02, 2003
IMPAX Receives FDA Approval for Generic Aralen
Oct 28, 2003
IMPAX Receives Final FDA Approval for Fenofibrate Capsules ANDA; Eighth ANDA Approval of 2003 for IMPAX
Oct 27, 2003
IMPAX Settles Patent Suit Related to Claritin-D 24-Hour
Oct 27, 2003
IMPAX Laboratories To Hold Third Quarter 2003 Financial Results Conference Call Wednesday, November 5, 2003
Oct 03, 2003
IMPAX Appoints Deloitte & Touche LLP as Independent Auditors
Aug 29, 2003
IMPAX Receives FDA Approval for Generic Urispas
Aug 04, 2003
IMPAX Announces Favorable Decision in Claritin Patent Appeal
Jul 31, 2003
IMPAX Signs Agreement With ANDRX and Teva for Generic Formulations of Wellbutrin® SR and ZYBAN®
Jul 28, 2003
IMPAX Reports Second Quarter Financial Results
Jul 22, 2003
IMPAX Laboratories to Hold Second Quarter 2003 Financial Results Conference Call Monday, July 28, 2003
Jun 17, 2003
IMPAX to Present at 13th Annual Wachovia Securities Nantucket Conference
May 28, 2003
IMPAX ANDA Filing for Generic Version of Wellbutrin SR® 200mg Tablets Accepted by FDA
May 19, 2003
IMPAX Shareholders Re-Elect Board Members
May 07, 2003
IMPAX Announces $25 Million Private Placement
Apr 30, 2003
IMPAX Reports Record First Quarter Results
Apr 28, 2003
IMPAX Receives FDA Approval for Generic Mestinon
Apr 24, 2003
IMPAX to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference
Apr 23, 2003
IMPAX Laboratories to Hold First Quarter 2003 Financial Results Conference Call Wednesday, April 30, 2003
Apr 09, 2003
IMPAX Announces Merck's Withdrawal of Lawsuit Related to Generic Version of Sinemet CR
Mar 28, 2003
IMPAX Prevails in Tricor Capsules Patent Infringement Suit
Mar 19, 2003
IMPAX to Present at Banc of America Healthcare Conference
Feb 28, 2003
IMPAX to Present at Lehman Brothers Global Healthcare Conference
Feb 24, 2003
IMPAX Comments on Merck's Lawsuit Related to Generic Version of Sinemet CR
Feb 12, 2003
IMPAX Reports Record Revenues in the Fourth Quarter and the Year 2002
Feb 05, 2003
IMPAX Laboratories to Hold Fourth Quarter & Year-End 2002 Financial Results Conference Call Wednesday, February 12, 2003
Jan 31, 2003
IMPAX Receives Final FDA Approval for a Generic Version of Claritin-D 12-Hour
Jan 30, 2003
IMPAX Receives FDA Approval for Generic Rilutek
Jan 27, 2003
IMPAX Comments on Abbott's Lawsuit Related to Generic Version Of Tricor
Jan 21, 2003
IMPAX Appoints Peter Terreri to Its Board of Directors
Jan 03, 2003
IMPAX Appoints Michael Wokasch Chief Operating Officer

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top